Divalproex

Divalproex is an anticonvulsant and mood-stabilizing medication approved across several products and formulations for the following uses:

• Bipolar disorder (acute mania/mixed episodes): Divalproex sodium extended-release tablets, divalproex sodium delayed-release tablets, Depakote ER, and Depakote delayed-release tablets are all approved to treat acute manic or mixed episodes in bipolar disorder. Note: controlled evidence supports short-term use (up to 3 weeks); long-term effectiveness in mania has not been established in controlled trials.
• Epilepsy — complex partial seizures: All divalproex products (tablets and capsules, delayed- and extended-release) are approved for monotherapy and add-on therapy of complex partial seizures in adults and children aged 10 and older.
• Epilepsy — absence seizures: All divalproex products are approved for simple and complex absence seizures, and as add-on therapy in patients with multiple seizure types that include absence seizures, in adults and children aged 10 and older.
• Migraine prevention: Divalproex sodium extended-release tablets, divalproex sodium delayed-release tablets, Depakote ER, and Depakote delayed-release tablets are approved for prevention of migraine headaches. This use is not approved for pregnant women or women of childbearing potential who are not using effective contraception.
• Depakote Sprinkle Capsules and divalproex sodium delayed-release capsules: Approved for epilepsy (complex partial and absence seizures) only — not for mania or migraine prevention.

After you swallow divalproex, it separates in the digestive tract into valproate, the active form. Valproate's exact mechanisms aren't fully known, but in epilepsy it is thought to work by increasing brain levels of GABA (gamma-aminobutyric acid) — a natural chemical that calms overactive nerve signals and helps prevent seizures. How it stabilizes mood in bipolar disorder is not established.

Divalproex is taken by mouth and comes in extended-release tablets (once daily), delayed-release tablets (in divided doses throughout the day), and delayed-release sprinkle capsules.

• Extended-release tablets (including Depakote ER): Taken once a day; swallow whole — do not crush or chew.
• Delayed-release tablets (including Depakote): Taken in divided doses; swallow whole — do not crush or chew. If you miss a dose, take it as soon as you remember unless your next dose is close — never double up.
• Delayed-release sprinkle capsules (including Depakote Sprinkle): Can be swallowed whole, or opened and sprinkled onto soft food — swallow the mixture immediately without chewing.

Doses are adjusted gradually based on your response and blood levels. Always follow your prescriber's instructions exactly.

The most commonly reported side effects of divalproex include:

• Nausea, vomiting, stomach pain, or diarrhea
• Drowsiness or sleepiness
• Tremor (shaking, especially of the hands)
• Dizziness
• Hair loss
• Headache
• Weight gain
• Low platelet count (thrombocytopenia), which can increase bleeding risk

Contact your doctor right away if you experience signs of liver trouble (unusual tiredness, facial swelling, vomiting, loss of appetite), severe stomach pain that could signal pancreatitis, unusual bleeding or bruising, sudden changes in mood or thoughts of self-harm, or confusion and sluggishness that could signal high ammonia levels in the blood.

• Liver failure: Fatal liver damage has occurred, most often in the first 6 months. Children under 2, people on multiple anticonvulsants, and those with mitochondrial disorders are most at risk. Liver tests are required before starting and throughout treatment.
• Serious fetal harm: Valproate exposure during pregnancy significantly increases the risk of spinal defects, other birth defects, lower IQ, autism spectrum disorder, and ADHD in the child. It is contraindicated for migraine prevention in pregnancy. For epilepsy or bipolar disorder, it should be used in pregnancy only when no other option works.
• Pancreatitis: Life-threatening pancreas inflammation can develop at any point — even after years of use. Severe abdominal pain, nausea, or vomiting require immediate medical evaluation.
• Suicidal thoughts: Like all antiepileptic drugs, divalproex increases the risk of suicidal thinking or behavior. Monitor for new or worsening depression or unusual mood changes.
• High ammonia (hyperammonemia): Elevated ammonia levels can cause confusion and reduced alertness — especially when taken with topiramate. Blood ammonia should be checked if unexplained mental changes occur.
• Bleeding risk: Divalproex can lower platelet counts and affect clotting. Regular monitoring is recommended.
• Severe allergic reactions: Rare but serious skin reactions and multi-organ hypersensitivity (DRESS syndrome) have been reported — stop the medication and seek care immediately.

Divalproex interacts with a number of commonly used medications — always tell every prescriber and pharmacist what you're taking:

• Phenytoin, carbamazepine, phenobarbital, primidone, rifampin: These drugs speed up valproate breakdown, lowering its levels and potentially reducing effectiveness.
• Felbamate: Raises valproate levels — a dose reduction may be needed.
• Carbapenem antibiotics (e.g., meropenem, ertapenem, imipenem): Can sharply reduce valproate blood levels, possibly triggering seizures; alternative antibiotics or anticonvulsants may be needed.
• Aspirin: Significantly increases the active (free) fraction of valproate in the blood — use with caution.
• Estrogen-containing hormonal contraceptives: May lower valproate levels; seizure frequency could increase.
• Topiramate: Combination raises the risk of dangerously high ammonia levels and abnormally low body temperature.
• Lamotrigine: Valproate dramatically increases lamotrigine levels; serious skin reactions (Stevens-Johnson syndrome) are possible — the lamotrigine dose must be reduced.
• Warfarin, amitriptyline/nortriptyline, phenobarbital, diazepam, ethosuximide, propofol, zidovudine: Divalproex affects blood levels of these drugs; dose adjustments and monitoring may be needed.
• Cannabidiol: Combination may raise liver enzyme levels (ALT/AST).

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

• Do not take divalproex if you have liver disease or significant liver dysfunction.
• Do not take it if you have a known urea cycle disorder — high ammonia and brain injury risk are serious.
• Do not take it if you have a mitochondrial disorder caused by POLG gene mutations (e.g., Alpers-Huttenlocher Syndrome); children under 2 who are suspected of having a mitochondrial disorder should also not take it.
• Pregnant women must not use divalproex for migraine prevention. For epilepsy or bipolar disorder, use only if other medications have failed, and use effective contraception.
• Women of childbearing potential should use reliable contraception throughout treatment and discuss the risks with their prescriber regularly.
• Children under age 2 are at considerably higher risk of fatal liver damage — use only with extreme caution and as a single agent if at all.
• Older adults should start at a lower dose, with more gradual increases, and be monitored closely for drowsiness, reduced food and fluid intake.
• Tell your doctor about all current medications, especially other seizure drugs, aspirin, antibiotics, hormonal contraceptives, antidepressants, and blood thinners.

Taking too much divalproex can cause extreme drowsiness, deep coma, irregular heartbeat (heart block), and high sodium levels in the blood — and has been fatal in some cases. If an overdose is suspected, seek emergency medical help immediately. Treatment in a hospital may include supportive care, and in severe cases, dialysis to help remove the drug from the body.

The relationship between valproate blood levels and how well it works isn't straightforward, partly because the drug binds tightly to blood proteins and that binding changes depending on the concentration. In epilepsy, total valproate blood levels between 50 and 100 mcg/mL are generally considered the therapeutic target, though some patients respond at different levels. In acute mania trials, patients were typically dosed to achieve trough blood levels between 85 and 125 mcg/mL. Certain groups — including older adults, people with liver or kidney disease, and those with high blood fat levels — may have more active (unbound) drug in their system than expected, which can affect both effectiveness and side effects.

Divalproex extended-release tablets are well absorbed — about 90% reaches the bloodstream after a meal — with peak blood levels occurring roughly 4 to 17 hours after a dose. The drug is processed almost entirely by the liver, mainly through a process called glucuronidation and fat metabolism (beta-oxidation), and less than 3% leaves the body unchanged through urine. The half-life (how long it takes the body to clear half of the drug) is typically 9 to 16 hours when taken alone, but can be shorter when taken with other seizure medications that speed up liver enzymes. Extended-release tablets taken once daily produce steadier blood levels (10–20% less fluctuation between peak and trough) compared to delayed-release tablets taken multiple times a day.

Store tablets at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) .